Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:depression
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:clinical_trial |
Phase III
|
| gptkbp:clinical_use |
acute treatment
maintenance treatment |
| gptkbp:contraindication |
severe renal impairment
hypersensitivity to paliperidone |
| gptkbp:dosage_form |
suspension
|
| gptkbp:duration |
long-term
|
| gptkbp:effective_date |
2010-10-29
|
| gptkbp:formulation |
long-acting injectable
|
| gptkbp:frequency |
once a month
|
| https://www.w3.org/2000/01/rdf-schema#label |
Invega Sustenna
|
| gptkbp:ingredients |
gptkb:paliperidone
|
| gptkbp:is_monitored_by |
gptkb:weight
renal function blood glucose lipid levels |
| gptkbp:manufacturer |
gptkb:Janssen_Pharmaceuticals
|
| gptkbp:marketed_as |
gptkb:Canada
gptkb:European_Union gptkb:United_States |
| gptkbp:mechanism_of_action |
dopamine D2 receptor antagonist
serotonin 5-HT2 A receptor antagonist |
| gptkbp:packaging |
pre-filled syringe
|
| gptkbp:patient_education |
recognizing side effects
importance of adherence regular follow-up appointments |
| gptkbp:patient_population |
adults
adolescents |
| gptkbp:pharmacokinetics |
once monthly dosing
steady-state concentration achieved after 4 months |
| gptkbp:regulatory_compliance |
controlled substance
prescription only |
| gptkbp:related_products |
gptkb:Sustenna
gptkb:Xeplion gptkb:Invega |
| gptkbp:route_of_administration |
intramuscular injection
|
| gptkbp:side_effect |
seizures
drowsiness cardiovascular events weight gain increased cholesterol hyperglycemia extrapyramidal symptoms neuroleptic malignant syndrome |
| gptkbp:storage |
store at 2° C to 8° C
|
| gptkbp:used_for |
treatment of schizoaffective disorder
treatment of schizophrenia |
| gptkbp:website |
deltoid muscle
gluteal muscle |
| gptkbp:bfsParent |
gptkb:Paliperidone
|
| gptkbp:bfsLayer |
6
|